Successful recovery of a patient with multiple myeloma from severe coronavirus disease 2019 (COVID‑19) pneumonia during the first chemotherapy cycle: A case report

Li,Ziping; Chen,Yan; Yang,Bohan; Song,Haiping; Chen,Wanxin; Zhou,Hao

doi:10.3892/etm.2021.9823

Successful recovery of a patient with multiple myeloma from severe coronavirus disease 2019 (COVID‑19) pneumonia during the first chemotherapy cycle: A case report

Authors:
- Ziping Li
- Yan Chen
- Bohan Yang
- Haiping Song
- Wanxin Chen
- Hao Zhou
View Affiliations

Affiliations: Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Respiratory and Critical Care Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China, Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430022, P.R. China
Published online on: February 24, 2021 https://doi.org/10.3892/etm.2021.9823
Article Number: 392

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

A continuing outbreak of pneumonia associated with the 2019 novel coronavirus (2019‑nCoV) was initially described in Wuhan, China in December 2019. Weak and elderly individuals, and those with chronic diseases such as hematological malignancies are prone to develop severe pneumonia. The humoral immunity of patients with multiple myeloma is prevalently low, and their inferior immunity further deteriorates during chemotherapy. For patients with onco‑hematological malignancies infected with 2019‑nCoV during the first chemotherapy cycle, the clinical treatment experience is lacking. The present study is a report of a 61‑year‑old patient newly diagnosed with multiple myeloma in the key 2019‑nCoV outbreak area, who suffered severe 2019‑nCoV pneumonia during the first chemotherapy cycle. The present case report demonstrated that a rapidly progressive and severe form of pneumonia was a specific clinical feature of COVID‑19, especially in immunocompromised patients with cancer. The treatment strategy combining timely suspending chemotherapy, early intervention using intravenous immunoglobulin, interferon α inhalation and oral antiviral drugs was effective. Therefore, in the pandemic environment, it is strongly recommend that the risk of 2019‑nCoV infection is assessed prior to chemotherapy.

View Figures

View References

1	Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al: China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 382:1708–1720. 2020. View Article : Google Scholar
2	Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ and Prescott HC: Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 324:782–793. 2020.PubMed/NCBI View Article : Google Scholar
3	Kazandjian D: Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 43:676–681. 2016.PubMed/NCBI View Article : Google Scholar
4	Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD, et al: Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016. JAMA Oncol. 4:1221–1227. 2018.PubMed/NCBI View Article : Google Scholar
5	Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A and Flowers CR: 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 66:443–459. 2016.PubMed/NCBI View Article : Google Scholar
6	Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, et al: CASTOR Investigators: Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma. N Engl J Med. 375:754–766. 2016.PubMed/NCBI View Article : Google Scholar
7	Durie BG and Salmon SE: A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 36:842–854. 1975.PubMed/NCBI View Article : Google Scholar
8	National Health Commission of People's Republic of China: Diagnosis and treatment of pneumonia caused by novel coronavirus (trial fifth edition). http://www.nhc.gov.cn/jkj/s3577/202002/a5d6f7b8c48c451c87dba14889b30147/files/3514cb996ae24e2faf65953b4ecd0df4.pdf. Accessed February 2, 2020 (In Chinese).
9	Mina MJ and Klugman KP: The role of influenza in the severity and transmission of respiratory bacterial disease. Lancet Respir Med. 2:750–763. 2014.PubMed/NCBI View Article : Google Scholar
10	Herold S, Becker C, Ridge KM and Budinger GR: Influenza virus-induced lung injury: Pathogenesis and implications for treatment. Eur Respir J. 45:1463–1478. 2015.PubMed/NCBI View Article : Google Scholar
11	Chertow DS and Memoli MJ: Bacterial coinfection in influenza: A grand rounds review. JAMA. 309:275–282. 2013.PubMed/NCBI View Article : Google Scholar
12	Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, Fan Y and Zheng C: Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study. Lancet Infect Dis. 20:425–434. 2020.PubMed/NCBI View Article : Google Scholar
13	Zhang X, Song K, Tong F, Fei M, Guo H, Lu Z, Wang J and Zheng C: First case of COVID-19 in a patient with multiple myeloma successfully treated with tocilizumab. Blood Adv. 4:1307–1310. 2020.PubMed/NCBI View Article : Google Scholar
14	Zhou Y, Fu B, Zheng X, Wang D, Zhao C, Qi Y, Sun R, Tian Z, Xu X and Wei H: Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients. Natl Sci Rev. 7:998–1002. 2020. View Article : Google Scholar
15	Drosten C, Seilmaier M, Corman VM, Hartmann W, Scheible G, Sack S, Guggemos W, Kallies R, Muth D, Junglen S, et al: Clinical features and virological analysis of a case of Middle East respiratory syndrome coronavirus infection. Lancet Infect Dis. 13:745–751. 2013.PubMed/NCBI View Article : Google Scholar
16	Rasche L, Weinhold N, Morgan GJ, van Rhee F and Davies FE: Immunologic approaches for the treatment of multiple myeloma. Cancer Treat Rev. 55:190–199. 2017.PubMed/NCBI View Article : Google Scholar
17	Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, et al: Cancer patients in SARS-CoV-2 infection: A nationwide analysis in China. Lancet Oncol. 21:335–337. 2020.PubMed/NCBI View Article : Google Scholar